

Sarat Chandarlapaty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9351688/publications.pdf>

Version: 2024-02-01

99
papers

15,504
citations

30070

54
h-index

32842

100
g-index

107
all docs

107
docs citations

107
times ranked

21129
citing authors

#	ARTICLE	IF	CITATIONS
1	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
2	Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell, 2011, 19, 575-586.	16.8	1,026
3	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Genetics, 2013, 45, 1439-1445.	21.4	960
4	AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity. Cancer Cell, 2011, 19, 58-71.	16.8	867
5	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
6	Unlocking the potential of antibody-drug conjugates for cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 327-344.	27.6	498
7	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene, 2011, 30, 2547-2557.	5.9	471
8	Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell, 2012, 22, 668-682.	16.8	469
9	Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Science Translational Medicine, 2015, 7, 313ra182.	12.4	460
10	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. JAMA Oncology, 2016, 2, 1310.	7.1	395
11	mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling. Cancer Discovery, 2011, 1, 248-259.	9.4	385
12	HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy, 2011, 11, 263-275.	2.4	368
13	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	16.8	307
14	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2078-2099.	1.6	303
15	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3761-3766.	7.1	291
16	Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discovery, 2017, 7, 277-287.	9.4	286
17	Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene, 2017, 36, 2255-2264.	5.9	283
18	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science Translational Medicine, 2015, 7, 283ra51.	12.4	276

#	ARTICLE	IF	CITATIONS
19	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183.	9.4	275
20	Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling. <i>PLoS ONE</i> , 2008, 3, e3065.	2.5	248
21	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259.	1.6	240
22	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
23	Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. <i>ELife</i> , 2016, 5, .	6.0	212
24	Feedback Suppression of PI3K [±] Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3K [±] . <i>Cancer Cell</i> , 2015, 27, 109-122.	16.8	203
25	Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer. <i>Cancer Discovery</i> , 2012, 2, 311-319.	9.4	188
26	PK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K [±] Inhibition. <i>Cancer Cell</i> , 2016, 30, 229-242.	16.8	187
27	Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3K [±] inhibitors. <i>Science</i> , 2019, 366, 714-723.	12.6	185
28	Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 6784-6791.	7.0	176
29	SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers. <i>Clinical Cancer Research</i> , 2008, 14, 240-248.	7.0	175
30	Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS [±] ERK Signaling. <i>Cancer Discovery</i> , 2014, 4, 334-347.	9.4	169
31	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor [±] Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2100-2108.	1.6	165
32	Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. <i>Nature Reviews Cancer</i> , 2018, 18, 377-388.	28.4	148
33	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using ⁸⁹ Zr-Trastuzumab PET/CT. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1523-1528.	5.0	146
34	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor [±] Positive Breast Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2736-2740.	1.6	141
35	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. <i>Nature Genetics</i> , 2015, 47, 1212-1219.	21.4	139
36	Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7575-7582.	6.4	127

#	ARTICLE	IF	CITATIONS
37	Reversible histone glycation is associated with disease-related changes in chromatin architecture. <i>Nature Communications</i> , 2019, 10, 1289.	12.8	123
38	PTEN is a protein tyrosine phosphatase for IRS1. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 522-527.	8.2	116
39	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2 ⁺ advanced breast cancer: results from BOLERO-2. <i>British Journal of Cancer</i> , 2017, 116, 726-730.	6.4	112
40	Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. <i>Oncogene</i> , 2010, 29, 325-334.	5.9	106
41	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018, 9, 1816.	12.8	105
42	KMT2C mediates the estrogen dependence of breast cancer through regulation of ER β enhancer function. <i>Oncogene</i> , 2018, 37, 4692-4710.	5.9	102
43	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	13.2	96
44	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2 ⁺ Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2804-2807.	1.6	93
45	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 154-160.	2.4	91
46	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	91
47	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	9.4	83
48	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. <i>Annals of Oncology</i> , 2016, 27, 1443-1448.	1.2	79
49	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. <i>Cancer Cell</i> , 2018, 34, 852-862.e4.	16.8	73
50	The SERM/SERD basedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. <i>ELife</i> , 2018, 7, .	6.0	72
51	Head-to-Head Evaluation of ¹⁸ F-FES and ¹⁸ F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 326-331.	5.0	69
52	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
53	INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. <i>Cancer Discovery</i> , 2022, 12, 356-371.	9.4	68
54	Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. <i>Oncolmmunology</i> , 2017, 6, e1267891.	4.6	66

#	ARTICLE	IF	CITATIONS
55	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. <i>JAMA Oncology</i> , 2020, 6, 84.	7.1	66
56	Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 2612-2635.	1.6	60
57	Independent real-world application of a clinical-grade automated prostate cancer detection system. <i>Journal of Pathology</i> , 2021, 254, 147-158.	4.5	57
58	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	7.0	54
59	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018, 11, .	3.6	53
60	Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. <i>Molecular Cell</i> , 2021, 81, 708-723.e5.	9.7	51
61	New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 803-808.	2.8	47
62	HER2-positive breast cancers evade anti-HER2 therapy via a switch in driver pathway. <i>Nature Communications</i> , 2021, 12, 6667.	12.8	47
63	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹ Zr-Pertuzumab PET/CT. <i>Radiology</i> , 2020, 296, 370-378.	7.3	40
64	Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. <i>Breast Cancer Research</i> , 2019, 21, 82.	5.0	35
65	Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 2636-2655.	1.6	34
66	Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 91-97.	2.5	33
67	Accelerating drug development in breast cancer: New frontiers for ER inhibition. <i>Cancer Treatment Reviews</i> , 2022, 109, 102432.	7.7	28
68	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	5.2	27
69	AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	24
70	Mutant SF3B1 promotes AKT- and NF- κ B-driven mammary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	22
71	Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.9	20
72	Immunohistochemical assessment of HRASQ61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020, 76, 865-874.	2.9	19

#	ARTICLE	IF	CITATIONS
73	Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. <i>Journal of Clinical Oncology</i> , 2019, 37, 1148-1150.	1.6	17
74	Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients. <i>Annals of Oncology</i> , 2020, 31, 991-1000.	1.2	17
75	Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 742-752.	2.8	17
76	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 43.	5.2	16
77	Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1226-1235.	0.5	15
78	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050.	2.9	15
79	A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i> -Mutated HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3867-3875.	7.0	15
80	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. <i>Cancer Discovery</i> , 2022, 12, 2120-2139.	9.4	14
81	Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	13
82	Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors. <i>Journal of Clinical Oncology</i> , 2019, 37, 1009-1009.	1.6	13
83	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz049.	2.9	11
84	Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 44.	5.2	11
85	ESR1 and endocrine therapy resistance: more than just mutations. <i>Annals of Oncology</i> , 2018, 29, 787-789.	1.2	10
86	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. <i>Modern Pathology</i> , 2019, 32, 81-87.	5.5	10
87	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. <i>Genome Medicine</i> , 2020, 12, 78.	8.2	10
88	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β -Catenin Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 573-584.	3.4	10
89	Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. <i>Modern Pathology</i> , 2022, 35, 396-402.	5.5	9
90	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9

#	ARTICLE	IF	CITATIONS
91	Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. ACS Chemical Biology, 2018, 13, 3374-3384.	3.4	8
92	Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer. Molecular Cancer Research, 2021, 19, 1559-1570.	3.4	6
93	The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. Cancer Research, 2022, 82, 2269-2280.	0.9	6
94	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. Journal of Clinical Pathology, 2020, , jclinpath-2020-207052.	2.0	5
95	<scp>Wholeâ€xome</scp> sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. Journal of Pathology: Clinical Research, 2021, 7, 113-120.	3.0	4
96	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. JCO Precision Oncology, 2021, 5, 6-16.	3.0	2
97	Resistance to PI3K Pathway Inhibition. Cancer Drug Discovery and Development, 2016, , 125-147.	0.4	2
98	Recurrent <i>WWTR1</i><scp>S89W</scp> mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. Journal of Pathology, 2022, 257, 635-649.	4.5	2
99	Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. JCO Precision Oncology, 2020, 4, 1217-1223.	3.0	1